Clinical trial · Interventional
One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population
An Open-label, Multi-centre, Randomised, Parallel-group Trial, Comparing Efficacy and Safety of Degarelix One-month Dosing Regimen With Goserelin in Chinese Patients With Prostate Cancer Requiring Androgen Ablation Therapy
NCT01744366CI-TRIAL-00018345PANDAcompletedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
One month degarelix/comparator treatment for prostate cancer in Chinese population
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Degarelix
- description
- Degarelix 240/80 mg
- interventionNames
- Drug: Degarelix
- type
- ACTIVE_COMPARATOR
- label
- Goserelin
- description
- Goserelin 3.6 mg
- interventionNames
- Drug: Goserelin
Primary outcomes (1)
- measure
- Cumulative probability of testosterone at castrate level (≤0.5 ng/mL)
- timeFrame
- Day 28 to Day 364
Secondary outcomes (8)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Chinese male over 18 years * Adenocarcinoma of the prostate * Relevant disease status based on lab values and as judged by the physician * Life expectancy of at least a year Exclusion Criteria: * Previous hormonal treatment for prostate cancer * Considered to be candidate for curative therapy * Risk or history of any serious or significant health condition * Has received an investigational drug within the last 28 days and no previous treatment with degarelix
References
Publications (1)
- DERIVEDZengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Blumle A, Schmucker C, Mayer B, Kunath F. Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD012548. doi: 10.1002/14651858.CD012548.pub2. PMID 34350976